A Phase 3 interventional study of Baricitinib and Placebo in Systemic Lupus Erythematosus, sponsored by Eli Lilly and Company. Terminated at 297 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-16.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Lupus Erythematosus, Systemic · Eli Lilly and Company.
Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 7 in phase 3, and was the 8th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →1 of the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company is open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Australia, China, Japan
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,147 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 778 across the 11 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).
Inclusion Criteria:
Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally every day (QD).
Drug: Baricitinib · Drug: Placebo
Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD.
Drug: Baricitinib · Drug: Placebo
Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 2 mg Baricitinib administered orally QD.
Drug: Baricitinib · Drug: Placebo
Participants who received placebo in the originating study (JAHZ or JAIA) were randomized to receive 4 mg Baricitinib administered orally QD.
Drug: Baricitinib · Drug: Placebo
Administered orally.
Also known as: LY3009104
Administered orally.
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Percentage of participants with TEAEs. A treatment-emergent AE (TEAE) is defined as an event that first occurred or worsened in severity after the first dose of study treatment in Study JAIM and on or prior to the last visit date during the analysis period. The analysis period is defined as the treatment period plus up to 30 days off-drug follow-up time. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Week 134
Percentage of Participants With Adverse Events of Special Interest (AESIs)
Percentage of Participants with AESIs. AESI consisted of infections, positively adjudicated arterial thromboembolic events (ATE), positively adjudicated venous thromboembolic events (VTE), positively adjudicated major adverse cardiovascular events (MACE), other positively adjudicated cardiovascular events, death, anaphylactic reactions, hypersensitivity, angioedema, and malignancies.
Time frame: Week 134
Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of participants with SAEs. An SAE is any AE from this study that results in one of the following outcomes: Death; Initial or prolonged inpatient hospitalization; A life-threatening experience (that is, immediate risk of dying); Persistent or significant disability/incapacity; Congenital anomaly/birth defect; Important medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above. A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Week 134
Percentage of Participants With Temporary Investigational Product Interruptions
Percentage of participants with temporary investigational product interruptions.
Time frame: Week 134
Percentage of Participants With Permanent Investigational Product Discontinuations
Percentage of participants with permanent investigational product discontinuations.
Time frame: Week 134
Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response
SRI-4 response defined as 1)greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assesses disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).
Time frame: Week 134
Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)
Percentage of participants achieving a LLDAS. The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg daily.
Time frame: Week 48
Change From Baseline in Prednisone Dose
Change from baseline in prednisone dose.
Time frame: Baseline through Week 48
Annualized Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index Flare Rate
The SELENA-SLEDAI tool is a cumulative and weighted index used to assess disease activity across 24 different disease descriptors in patients with lupus. A patient's SELENA-SLEDAI total score is the sum of all marked lupus related descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, leukopenia). A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity. The annualized flare rate is calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25.
Time frame: Baseline through Week 48
Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score
The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations.
Time frame: Week 48
Change From Baseline in Tender Joint Count
The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
Time frame: Baseline through Week 48
Change From Baseline in Swollen Joint Count
The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
Time frame: Baseline trough Week 48
Change From Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Total Score
The SLICC/ACR damage index is a validated instrument to assess damage, defined as irreversible impairment, continuously persistent for 6 months (ascertained by clinical assessment), occurring since the onset of lupus, and it is based on a weighted scoring system. This index records damage occurring in participants with SLE regardless of cause, with demonstrated content, face, criterion, and discriminant validity. A score of 0 indicates no damage. Total maximum score is 47 and increasing score indicates increasing disease severity.
Time frame: Baseline through Week 48
Change From Baseline in Worst Pain Numeric Rating Scale (NRS)
Change from baseline in Worst Pain NRS. It is assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". Overall severity of a patient's pain is indicated by selecting the number that best describes the worst level of pain during the past 7 days.
Time frame: Baseline through Week 48
Participants who completed originating study \[I4V-MC-JAHZ (NCT03616912) or Study I4V-MC-JAIA (NCT03616964)\] were enrolled in this study.
| Milestone | 2 Milligrams (mg) Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Started | 388 | 379 | 189 | 191 |
| Safety population | 388 | 378 | 189 | 191 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 388 | 379 | 189 | 191 |
| Withdrew: Adverse event | 17 | 13 | 5 | 9 |
| Withdrew: Death | 0 | 6 | 2 | 0 |
| Withdrew: Lack of efficacy | 14 | 11 | 9 | 4 |
| Withdrew: Lost to follow-up | 3 | 4 | 0 | 2 |
| Withdrew: Other | 12 | 14 | 3 | 4 |
| Withdrew: Due to epidemic/pandemic | 1 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 318 | 318 | 163 | 163 |
| Withdrew: Withdrawal by subject | 23 | 12 | 6 | 9 |
| Withdrew: Missing data | 0 | 1 | 1 | 0 |
Percentage of participants with TEAEs. A treatment-emergent AE (TEAE) is defined as an event that first occurred or worsened in severity after the first dose of study treatment in Study JAIM and on or prior to the last visit date during the analysis period. The analysis period is defined as the treatment period plus up to 30 days off-drug follow-up time. A summary of serious and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
| Percentage of Participants | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | 61.9 | 68.8 | 65.1 | 64.4 |
Percentage of Participants with AESIs. AESI consisted of infections, positively adjudicated arterial thromboembolic events (ATE), positively adjudicated venous thromboembolic events (VTE), positively adjudicated major adverse cardiovascular events (MACE), other positively adjudicated cardiovascular events, death, anaphylactic reactions, hypersensitivity, angioedema, and malignancies.
| Percentage of participants | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Infections | 38.4 | 42.1 | 36.5 | 35.1 |
| Positively adjudicated ATE | 0.3 | 0.8 | 0.5 | 0.5 |
| Positively adjudicated VTE | 0.3 | 1.1 | 0.5 | 0.5 |
| Positively adjudicated MACE | 0.3 | 0.8 | 0.5 | 0.5 |
| Other positively adjudicated cardiovascular events | 0.3 | 0.8 | 0 | 0.5 |
| Death | 0 | 1.6 | 1.1 | 0 |
| Anaphylactic reactions | 3.6 | 4.2 | 5.8 | 3.1 |
| Hypersensitivity | 3.6 | 4.2 | 5.8 | 3.1 |
| Angioedema | 1.3 | 0.8 | 1.6 | 0 |
| Malignancies | 0.5 | 0.3 | 0 | 0 |
Percentage of participants with SAEs. An SAE is any AE from this study that results in one of the following outcomes: Death; Initial or prolonged inpatient hospitalization; A life-threatening experience (that is, immediate risk of dying); Persistent or significant disability/incapacity; Congenital anomaly/birth defect; Important medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above. A summary of all SAE's, regardless of causality, is located in the Reported Adverse Events section.
| Percentage of Participants | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) | 11.1 | 13.5 | 11.1 | 11.5 |
Percentage of participants with temporary investigational product interruptions.
| Percentage of Participants | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Percentage of Participants With Temporary Investigational Product Interruptions | 19.1 | 24.6 | 18.5 | 23.6 |
Percentage of participants with permanent investigational product discontinuations.
| Percentage of Participants | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Percentage of Participants With Permanent Investigational Product Discontinuations | 5.2 | 5.8 | 4.2 | 5.8 |
SRI-4 response defined as 1)greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of \>=0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assesses disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).
| Percentage of participants | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response | 0 | 0 | 0 | 0 |
Percentage of participants achieving a LLDAS. The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg daily.
| Percentage of participants | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS) | 29.8 | 33.0 | 19.4 | 26.0 |
Change from baseline in prednisone dose.
| milligrams (mg) | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Change From Baseline in Prednisone Dose | 2.35 ± 0.305 | 2.27 ± 0.316 | 1.68 ± 0.426 | 1.00 ± 0.419 |
The SELENA-SLEDAI tool is a cumulative and weighted index used to assess disease activity across 24 different disease descriptors in patients with lupus. A patient's SELENA-SLEDAI total score is the sum of all marked lupus related descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, leukopenia). A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity. The annualized flare rate is calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25.
| flares per year | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Annualized Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index Flare Rate | 0.978 | 0.926 | 0.894 | 0.746 |
The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations.
| Percentage of participants | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥10 at Baseline With ≥50% Reduction in CLASI Total Activity Score | 55.9 | 64.0 | 60.0 | 20.0 |
The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
| tender joints | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Change From Baseline in Tender Joint Count | -5.68 ± 0.281 | -5.85 ± 0.292 | -3.62 ± 0.383 | -3.73 ± 0.376 |
The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K \<10; \>=10), baseline corticosteroid dose (\<10 mg/day; \>=10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.
| swollen joints | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Change From Baseline in Swollen Joint Count | -4.03 ± 0.191 | -4.01 ± 0.196 | -3.19 ± 0.264 | -2.94 ± 0.257 |
The SLICC/ACR damage index is a validated instrument to assess damage, defined as irreversible impairment, continuously persistent for 6 months (ascertained by clinical assessment), occurring since the onset of lupus, and it is based on a weighted scoring system. This index records damage occurring in participants with SLE regardless of cause, with demonstrated content, face, criterion, and discriminant validity. A score of 0 indicates no damage. Total maximum score is 47 and increasing score indicates increasing disease severity.
| Score on a scale | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Change From Baseline in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Total Score | -0.03 ± 0.569 | -0.04 ± 0.544 | -0.04 ± 0.754 | -0.06 ± 0.505 |
Change from baseline in Worst Pain NRS. It is assessed using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". Overall severity of a patient's pain is indicated by selecting the number that best describes the worst level of pain during the past 7 days.
| Score on a scale | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Change From Baseline in Worst Pain Numeric Rating Scale (NRS) | -0.96 ± 0.167 | -1.23 ± 0.173 | -0.55 ± 0.222 | -0.83 ± 0.218 |
Collected over Baseline through Study Completion (Up to 134 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2 mg Baricitinib | 0/388 (0%) | 43/388 (11.1%) | 54/388 (13.9%) |
| 4 mg Baricitinib | 6/378 (1.6%) | 53/378 (14%) | 54/378 (14.3%) |
| Placebo to 2 mg Baricitinib | 2/189 (1.1%) | 21/189 (11.1%) | 35/189 (18.5%) |
| Placebo to 4 mg Baricitinib | 0/191 (0%) | 22/191 (11.5%) | 29/191 (15.2%) |
| Event | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Covid-19Infections and infestations | 0/388 | 7/378 | 3/189 | 0/191 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 1/388 | 0/378 | 3/189 | 0/191 |
| Covid-19 pneumoniaInfections and infestations | 5/388 | 5/378 | 0/189 | 3/191 |
| Escherichia pyelonephritisInfections and infestations | 0/388 | 0/378 | 0/189 | 3/191 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 2/388 | 5/378 | 1/189 | 3/191 |
| CholelithiasisHepatobiliary disorders | 0/388 | 0/378 | 0/189 | 2/191 |
| Urinary tract infectionInfections and infestations | 0/388 | 2/378 | 1/189 | 2/191 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/388 | 0/378 | 0/189 | 2/191 |
| PneumoniaInfections and infestations | 4/388 | 1/378 | 1/189 | 0/191 |
| Cervical dysplasiaReproductive system and breast disorders | 2/361 | 1/356 | 0/181 | 0/176 |
| Event | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib |
|---|---|---|---|---|
| Covid-19Infections and infestations | 35/388 | 32/378 | 21/189 | 23/191 |
| Urinary tract infectionInfections and infestations | 20/388 | 22/378 | 17/189 | 7/191 |
All randomized participants.
| Age, Continuous(years) | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib | Total |
|---|---|---|---|---|---|
| Mean | 43.8 ± 12.68 | 43.8 ± 12.03 | 43.8 ± 11.85 | 43.5 ± 13.22 | 43.7 ± 12.41 |
| Sex: Female, Male(Participants) | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib | Total |
|---|---|---|---|---|---|
| Female | 361 | 357 | 181 | 176 | 1075 |
| Male | 27 | 22 | 8 | 15 | 72 |
| Race (NIH/OMB)(Participants) | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 21 | 16 | 13 | 11 | 61 |
| Asian | 79 | 77 | 44 | 41 | 241 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 32 | 36 | 19 | 19 | 106 |
| White | 249 | 241 | 109 | 115 | 714 |
| More than one race | 3 | 2 | 2 | 2 | 9 |
| Unknown or Not Reported | 4 | 7 | 2 | 3 | 16 |
| Region of Enrollment(Participants) | 2 mg Baricitinib | 4 mg Baricitinib | Placebo to 2 mg Baricitinib | Placebo to 4 mg Baricitinib | Total |
|---|---|---|---|---|---|
| United States | 66 | 68 | 28 | 30 | 192 |
| Czechia | 7 | 9 | 7 | 5 | 28 |
| Russia | 19 | 16 | 11 | 11 | 57 |
| Greece | 8 | 4 | 0 | 3 | 15 |
| South Korea | 7 | 7 | 2 | 2 | 18 |
| Netherlands | 1 | 1 | 0 | 0 | 2 |
| Austria | 1 | 1 | 0 | 0 | 2 |
| China | 17 | 18 | 10 | 6 | 51 |
| Poland | 27 | 28 | 11 | 13 | 79 |
| Brazil | 17 | 19 | 14 | 10 | 60 |
| France | 0 | 1 | 0 | 1 | 2 |
| Serbia | 18 | 15 | 3 | 7 | 43 |
| Chile | 12 | 7 | 4 | 4 | 27 |
| Croatia | 3 | 1 | 1 | 1 | 6 |
| Colombia | 11 | 13 | 8 | 7 | 39 |
| Argentina | 21 | 23 | 13 | 16 | 73 |
| Romania | 11 | 6 | 3 | 4 | 24 |
| Hungary | 16 | 13 | 5 | 5 | 39 |
| Japan | 6 | 9 | 4 | 5 | 24 |
| Philippines | 13 | 8 | 5 | 7 | 33 |
| United Kingdom | 3 | 3 | 3 | 1 | 10 |
| Switzerland | 0 | 0 | 2 | 0 | 2 |
| India | 20 | 20 | 13 | 12 | 65 |
| Spain | 3 | 9 | 6 | 3 | 21 |
| Belgium | 1 | 1 | 1 | 0 | 3 |
| Taiwan | 8 | 10 | 5 | 7 | 30 |
| Italy | 2 | 0 | 1 | 1 | 4 |
| Mexico | 40 | 40 | 15 | 17 | 112 |
| South Africa | 13 | 9 | 6 | 6 | 34 |
| Israel | 3 | 3 | 0 | 0 | 6 |
| Australia | 5 | 6 | 4 | 2 | 17 |
| Germany | 9 | 11 | 4 | 5 | 29 |
Showing the first 100 of 297 sites across 32 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2019 to primary completion in Apr 2022, 30 months.
Results were first posted in May 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib
Lupus Erythematosus, Systemic →